<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142431">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246739</url>
  </required_header>
  <id_info>
    <org_study_id>2010/297</org_study_id>
    <nct_id>NCT01246739</nct_id>
  </id_info>
  <brief_title>Adrenalectomy Versus Follow-up in Patients With Subclinical Cushings Syndrome</brief_title>
  <acronym>AUSC</acronym>
  <official_title>Adrenalectomy Versus Follow-up in Patients With Mild Hypercortisolism: a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incidental findings of adrenal tumours,&quot;incidentalomas&quot;, occur in 1-5 % in the general
      population and 10-25 % of these patients will exhibit biochemical mild hypercortisolism.
      Although the patients do not have clinical signs of classical Cushing's syndrome, they have
      an increased risk for hypertension, dyslipidemia, diabetes mellitus, osteoporosis and
      obesity.

      The hypothesis of the study is, that surgery of the adrenal adenoma responsible for the
      increased secretion of cortisol, will in part cure or ameliorate the metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of hypertension</measure>
    <time_frame>At two years after intervention</time_frame>
    <description>Normalization of hypertension according to classification of the World Health Organization (WHO) assessed by 24 hours blood pressure measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of diabetes mellitus</measure>
    <time_frame>At two years after intervention</time_frame>
    <description>Normalization of diabetes mellitus according to the criteria of the WHO and assessed by oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased body mass index (BMI) to &lt; 30</measure>
    <time_frame>At two years post intervention</time_frame>
    <description>Standard assessment of BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>At two years post intervention</time_frame>
    <description>Bone density assessed with dual energy x-ray absorptiometry (DEXA) at the lumbar spine and hip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>At two years post intervention</time_frame>
    <description>Triglyceride and cholesterol changes of whole serum and of the lipoprotein classes; low-density-lipoprotein (LDL), very-low-density-lipoprotein (VLDL) and high-density-lipoprotein (HDL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>At two years post intervention</time_frame>
    <description>Cardiac function assessed by echocardiography; left ventricular ejection fraction (EF), left ventricular end-diastolic diameter (LVDD), left ventricular mass index (LVMI), ratio between mitral peak velocity flow of the early filling wave and the atrial wave (E/A ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>At two years after intervention</time_frame>
    <description>Mini Mental State Examination (MMSE) for cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>At two years after intervention</time_frame>
    <description>Quality of Life assessed by the generic instrument short form 36 (SF-36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atherosclerosis</measure>
    <time_frame>At one and two years after intervention</time_frame>
    <description>Carotid ultrasound/duplex scans with evaluation of intimal thickness and plaques.
Blood pressure measurement for ankle index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Adrenal Tumour With Mild Hypercortisolism</condition>
  <arm_group>
    <arm_group_label>Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who are diagnosed with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), who are followed only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with adrenal tumour and with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), operated with adrenalectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adrenalectomy</intervention_name>
    <description>Adrenalectomy (open or laparoscopic)</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adrenal tumour with biochemical mild hypercortisolism defined as pathological
             dexamethasone suppression test (cortisol &gt; 50 nmol/L at 8.00 am after 1 mg
             dexamethasone at 10 pm, plus one of the following criteria

               -  Low or suppressed adrenocorticotropic hormone (ACTH)

               -  Low or suppressed dehydroepiandrosterone (DHEA)

               -  No or pathological circadian rhythm of cortisol

        Exclusion Criteria:

          -  Increased levels of 24 hours urinary excretion of cortisol

          -  Pregnancy or lactation

          -  Inability to understand information or to comply with scheduled follow-up

          -  Mild hypercortisolism with bilateral adrenal tumours, without a gradient
             (lateralization on venous sampling)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders OJ Bergenfelz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Skåne University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders OJ Bergenfelz, MD, PhD</last_name>
    <phone>+4646172086</phone>
    <email>anders.bergenfelz@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erik Nordenström, MD, PhD</last_name>
    <phone>+4646172305</phone>
    <email>erik.nordenstrom@skane.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skåne University Hospital-Lund, Department of Surgery</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erik Nordenström, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Almqvist, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 5, 2016</lastchanged_date>
  <firstreceived_date>November 18, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild hypercortisolism</keyword>
  <keyword>adrenal tumour</keyword>
  <keyword>surgical procedures, elective</keyword>
  <keyword>indication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
